Recruiting
Phase 2
Phase 3

BLU-263

Sponsor:

Blueprint Medicines Corporation

Code:

NCT04910685

Conditions

Indolent Systemic Mastocytosis

Smoldering Systemic Mastocytosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elenestinib

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-11. This information was provided to ClinicalTrials.gov by Blueprint Medicines Corporation on 2025-04-30.